Share Product Development and Regulatory Information in the Areas of Non clinical, 91AV, Manufacturing and Control (CMC), and Clinical Development of Oligonucleotide-based Therapeutic Drugs
CONFERENCE HIGHLIGHTS
Opening Plenary Session: Emerging Technologies and Therapeutic Approaches
Two Keynote Sessions:
Craig C. Mello, PhD, University of Massachusetts Medical School; 2006 Nobel Laureate.
Alan B. Sachs, MD, PhD, Merck Research Laboratories.
Closing Plenary Session: Panel Discussion.
PARALLEL TRACKS
Track A – Non clinical Track.
Track B – 91AV, Manufacturing, and Controls (CMC) Track.
Track C – Clinical Development Track.
CONFERENCE HIGHLIGHTS
Opening Plenary Session: Emerging Technologies and Therapeutic Approaches
Two Keynote Sessions:
Craig C. Mello, PhD, University of Massachusetts Medical School; 2006 Nobel Laureate.
Alan B. Sachs, MD, PhD, Merck Research Laboratories.
Closing Plenary Session: Panel Discussion.
PARALLEL TRACKS
Track A – Non clinical Track.
Track B – 91AV, Manufacturing, and Controls (CMC) Track.
Track C – Clinical Development Track.
